DE60139320D1 - Auf faktor viia inhibitorisch wirkende (thio)-harnstoff- verbindingen, verfahren zu deren herstellung und deren verwendung - Google Patents

Auf faktor viia inhibitorisch wirkende (thio)-harnstoff- verbindingen, verfahren zu deren herstellung und deren verwendung

Info

Publication number
DE60139320D1
DE60139320D1 DE60139320T DE60139320T DE60139320D1 DE 60139320 D1 DE60139320 D1 DE 60139320D1 DE 60139320 T DE60139320 T DE 60139320T DE 60139320 T DE60139320 T DE 60139320T DE 60139320 D1 DE60139320 D1 DE 60139320D1
Authority
DE
Germany
Prior art keywords
harn
thio
production
factor viia
material compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60139320T
Other languages
German (de)
English (en)
Inventor
Otmar Klingler
Manfred Schudok
Hans-Peter Nestler
Hans Matter
Herman Schreuder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Application granted granted Critical
Publication of DE60139320D1 publication Critical patent/DE60139320D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18Ethylenedioxybenzenes, not substituted on the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60139320T 2000-06-06 2001-05-26 Auf faktor viia inhibitorisch wirkende (thio)-harnstoff- verbindingen, verfahren zu deren herstellung und deren verwendung Expired - Lifetime DE60139320D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00112116A EP1162194A1 (en) 2000-06-06 2000-06-06 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
PCT/EP2001/006029 WO2001094301A2 (en) 2000-06-06 2001-05-26 Factor viia inhibitory (thio)urea derivatives, their preparation and their use

Publications (1)

Publication Number Publication Date
DE60139320D1 true DE60139320D1 (de) 2009-09-03

Family

ID=8168926

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60139320T Expired - Lifetime DE60139320D1 (de) 2000-06-06 2001-05-26 Auf faktor viia inhibitorisch wirkende (thio)-harnstoff- verbindingen, verfahren zu deren herstellung und deren verwendung

Country Status (29)

Country Link
US (1) US6743790B2 (enExample)
EP (2) EP1162194A1 (enExample)
JP (1) JP4809570B2 (enExample)
KR (1) KR101011345B1 (enExample)
CN (1) CN1208314C (enExample)
AR (1) AR030936A1 (enExample)
AU (2) AU7749401A (enExample)
BR (1) BR0111264A (enExample)
CA (1) CA2410862C (enExample)
CZ (1) CZ20023963A3 (enExample)
DE (1) DE60139320D1 (enExample)
DK (1) DK1299354T3 (enExample)
EE (1) EE200200617A (enExample)
ES (1) ES2330412T3 (enExample)
HR (1) HRP20020961A2 (enExample)
HU (1) HUP0301631A2 (enExample)
IL (2) IL153220A0 (enExample)
MX (1) MXPA02009789A (enExample)
MY (1) MY129363A (enExample)
NO (1) NO328546B1 (enExample)
NZ (1) NZ522960A (enExample)
PL (1) PL359584A1 (enExample)
PT (1) PT1299354E (enExample)
RU (1) RU2286337C2 (enExample)
SK (1) SK17032002A3 (enExample)
TW (1) TWI283662B (enExample)
WO (1) WO2001094301A2 (enExample)
YU (1) YU89202A (enExample)
ZA (1) ZA200209018B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483228C (en) * 2002-04-27 2011-07-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Carboxamides
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
JP2007500221A (ja) * 2003-05-20 2007-01-11 ジェネンテック・インコーポレーテッド 第VIIa因子のベンゾフラン阻害剤
EP1628954A2 (en) * 2003-05-20 2006-03-01 Genentech, Inc. Acylsulfamide inhibitors of factor viia
JP2007501844A (ja) * 2003-08-08 2007-02-01 トランス テック ファーマ,インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
WO2006041119A1 (ja) * 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. ヒドラジド誘導体
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1856037A1 (en) * 2005-02-24 2007-11-21 Novo Nordisk Health Care AG Amidino-compounds for stabilizing factor vii polypeptide formulations
US20090041747A1 (en) * 2005-02-24 2009-02-12 Novo Nordisk Health Care Ag Compounds for Stabilizing Factor VII Polypeptide Formulations
JP2008531524A (ja) * 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Vii因子ポリペプチド製剤を安定化する化合物
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
MY146537A (en) 2006-03-24 2012-08-15 Eisai R&D Man Co Ltd Triazolone derivative
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
EP2202231A4 (en) 2007-09-21 2011-09-28 Eisai R&D Man Co Ltd 2,3-DIHYDROIMINOISOINDOLE DERIVATIVE
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
SI2770989T1 (sl) 2011-10-26 2018-12-31 Allergan, Inc. Aminokisline, substituirane z amidnimi derivati N-sečnine, kot so modulatorji receptorja za formil peptidnemu receptorju podobni receptor(FPRL-1)
AU2013249474A1 (en) * 2012-04-16 2014-11-06 Allergan, Inc. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
CN104717973A (zh) * 2012-10-10 2015-06-17 诺和诺德保健Ag(股份有限公司) 因子vii多肽的液体药物组合物
MX364916B (es) 2013-03-06 2019-05-13 Allergan Inc Uso de agonistas de receptor de péptido formilo 2 para tratar enfermadades inflamatorias oculares.
KR20210024691A (ko) 2013-03-06 2021-03-05 알러간, 인코포레이티드 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
WO1992013552A1 (en) * 1991-02-05 1992-08-20 Smithkline Beecham Corporation Anti-aggregatory peptides containing an aromatic ester or amide
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
JP3387948B2 (ja) * 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
GB9313269D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Allophanic acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists
CN1076345C (zh) * 1993-10-19 2001-12-19 住友制药株式会社 2,3-二氨基丙酸衍生物
US5674894A (en) * 1995-05-15 1997-10-07 G.D. Searle & Co. Amidine derivatives useful as platelet aggregation inhibitors and vasodilators
CA2243507A1 (en) * 1996-01-30 1997-08-07 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
CN100418951C (zh) * 1997-11-18 2008-09-17 帝人医药株式会社 环胺衍生物及其作为药物的用途
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors

Also Published As

Publication number Publication date
MXPA02009789A (es) 2003-03-12
HK1055941A1 (en) 2004-01-30
ES2330412T3 (es) 2009-12-10
EP1162194A1 (en) 2001-12-12
AR030936A1 (es) 2003-09-03
NO20025810L (no) 2002-12-03
PT1299354E (pt) 2009-10-01
EP1299354B1 (en) 2009-07-22
WO2001094301A2 (en) 2001-12-13
YU89202A (sh) 2006-05-25
AU2001277494B2 (en) 2006-05-04
ZA200209018B (en) 2003-10-08
HRP20020961A2 (en) 2004-12-31
CN1208314C (zh) 2005-06-29
EE200200617A (et) 2004-04-15
SK17032002A3 (sk) 2003-05-02
WO2001094301A3 (en) 2002-04-04
HUP0301631A2 (hu) 2003-09-29
US20020052417A1 (en) 2002-05-02
IL153220A0 (en) 2003-07-06
BR0111264A (pt) 2003-06-17
IL153220A (en) 2008-11-03
PL359584A1 (en) 2004-08-23
DK1299354T3 (da) 2009-11-16
NO328546B1 (no) 2010-03-15
JP4809570B2 (ja) 2011-11-09
NO20025810D0 (no) 2002-12-03
EP1299354A2 (en) 2003-04-09
CA2410862C (en) 2009-11-10
US6743790B2 (en) 2004-06-01
KR101011345B1 (ko) 2011-01-28
AU7749401A (en) 2001-12-17
KR20030007911A (ko) 2003-01-23
CA2410862A1 (en) 2001-12-13
CN1427818A (zh) 2003-07-02
MY129363A (en) 2007-03-30
RU2286337C2 (ru) 2006-10-27
TWI283662B (en) 2007-07-11
CZ20023963A3 (cs) 2003-03-12
NZ522960A (en) 2004-05-28
JP2003535844A (ja) 2003-12-02

Similar Documents

Publication Publication Date Title
DE60139320D1 (de) Auf faktor viia inhibitorisch wirkende (thio)-harnstoff- verbindingen, verfahren zu deren herstellung und deren verwendung
DE60029350D1 (de) Mehrschichtiges mit einer lotion getränktes taschentuch und verfahren zu dessen herstellung
DE60143706D1 (de) Absorbens und verfahren zu dessen herstellung, absorbierbare artikel und syntheseprodukte
DE50110902D1 (de) Farb- und/oder effektgebende mehrschichtlackierung, verfahren zu ihrer herstellung und ihre verwendung
ATE370946T1 (de) 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
DE60036294D1 (de) Umgossener transponder und verfahren zu dessen herstellung
DE60013321D1 (de) Antimikrobieller absorbierender artikel und verfahren zu seiner herstellung und verwendung
DE69940075D1 (de) Organisch-inorganisch gradiertes mehrschichtmaterial sowie verfahren zu dessen herstellung und benutzung
DE60023023D1 (de) Zirkoniumdioxidsol und verfahren zu seiner herstellung
DE69936005D1 (de) Mehrschichtverpackungsmaterial und verfahren zur herstellung desselben
ATE379971T1 (de) Disinfektionsmittel und verfahren zu dessen herstellung
DE69922186D1 (de) 1-(1-subst.-4-piperidinyl)methyl]-4-piperidin-derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung
ATE308525T1 (de) Hydantoin-, thiohydantoin-, pyrimidinedion- und thioxopyrimidinon-derivate, verfahren zur ihrer herstellung und ihre anwendung als arztneimittel
DE69838065D1 (de) Aerosolprodukte und verfahren zu deren herstellung
ATE232879T1 (de) Erythromycin-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE60103395D1 (de) 1,4-diazabicyclo[3.2.2]nonanbenzoxazol-, benzothiazol- und benzoimidazolderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DE59914950D1 (de) Feldeffektgesteuerter transistor und verfahren zu dessen herstellung
DE60236790D1 (de) Piezoelektrischer oszillator und verfahren zu seiner herstellung
DE60323689D1 (de) Schräg geschichtetes furniermaterial und verfahren zu dessen herstellung
DE50011179D1 (de) Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60012288D1 (de) Antivirale pyrimidindion-derivate und verfahren zu ihrer herstellung
DE50010354D1 (de) Verbundteil und verfahren zu dessen herstellung
ATE329947T1 (de) Polyolefinzusammensetzung, verfahren zur herstellung und die verwendung davon
DE60038384D1 (de) Polyarylen und verfahren zu dessen herstellung
DE50206824D1 (de) Befestigungselement und verfahren zu seiner herstellung sowie verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition